Predicting progression to myeloid malignancy. (A) Four potential outcomes of expanded CH clones are depicted. (B-D) Three examples of risk forecasting by MN-Predict, a recently developed web-based tool for qualification of the future risks of different types of myeloid neoplasm (MN).⁶⁶ MN-Predict forecasts an individual’s risks of AML, MDS, and MPN over the subsequent 15 years based on their age, sex, genetic data (mutated CH gene and variant allele fraction [VAF]), and specific complete blood count and biochemistry parameters. The examples illustrate baseline risk forecasting for 3 UK Biobank participants with the indicated characteristics who went on to develop the specified MN (panels B, AML; C, MDS; and D, MPN) after the depicted latency.